Amzak Health Portfolio


  • Eidos Therapeutics is developing a novel drug to treat all forms of Transthyretin (TTR) amyloidosis, a condition characterized by toxic amyloid aggregates in the heart and peripheral nerves. The lead candidate, AG10 is an orally-administered, small molecule designed to mimic a naturally-occurring genetic rescue mutation that protects high-risk individuals from developing TTR amyloidosis.
    Headquarters: San Francisco, California

  • GTx, Inc. (NASDAQ: GTXI) is a clinical stage biotechnology company focused on developing small molecules that selectively modulate the effects of certain hormones produced by the body. The company is moving forward selective androgen receptor modulators, also referred to as SARMs, to potentially treat a number of diseases such as stress urinary incontinence.
    Headquarters: Memphis, Tennessee

  • Selecta Biosciences, Inc.(NASDAQ: SELB) is a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses. Selecta is combining its tolerogenic Synthetic Vaccine Particles (SVP™) to a range of biologics for rare and serious diseases that require new treatment options. SEL-212, the company's lead candidate is being developed to treat severe gout patients.
    Headquarters: Watertown, Massachusetts

Specialty Pharmaceutical:

  • Zosano Pharma (NASDAQ: ZSAN) has developed a proprietary transdermal delivery system to administer novel formulations of existing drugs through the skin for the treatment of a variety of indications. Company's lead program ADAM Zolmitriptan (M207) is a transdermal formulation of zolmitriptan designed to provide rapid relief of migraine symptoms in a discreet and simple manner.
    Headquarters: Fremont, California

  • Teligent (NASDAQ: TLGT) engages in the formulation, development, manufacture, and packaging of topical semi-solid and liquid products for pharmaceutical, cosmeceutical, and cosmetic customers in the United States.
    Headquarters: Buena, New Jersey

Medical Technology:

  • Essential Medical is a medical technology company developing best-in-class vascular closure devices for femoral punctures following cardiac catheterization procedures. These procedures, such as TAVR and EVAR, are some of the fastest growing segments within interventional cardiology, highlighting the need for fast, easy and uncomplicated arterial closure solutions.
    Headquarters: Malvern, Pennsylvania

  • Inspire Medical Systems, Inc. developed the world's first fully implantable neurostimulation system for treatment of obstructive sleep apnea. The device works by opening up the upper airway in synchrony with patient's breathing during sleep through gentle stimulation of the key airway muscles. It offers a safe, effective and minimally invasive alternative to millions of patients who have failed or are intolerant of Continuous Positive Airway Pressure (CPAP).
    Headquarters: Maple Grove, Minnesota

  • KEW Group Inc. (KEW) is revolutionizing cancer care by empowering oncologists with access to genomic insights to design optimal, individualized treatment approaches for patients.  KEW Group’s comprehensive set of products and solutions are designed to provide clarity above the complexity of genome-guided, personalized cancer therapy, arming oncologists with knowledge, informing today’s treatment decisions, and guiding tomorrow’s new therapies.
    Headquarters: Cambridge, Massachusetts